Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Observational

Evaluating the Clinical Utility of Modified Ventilator-Associated Event Criteria in Predicting ICU Mortality and Ventilator Duration: Can Less Restrictive Definitions Improve Prediction?

NCT07212881 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2025-03-01
Last updated
2025-10-08

Condition(s) studied

Ventilator-Associated Events

Study summary

Study design: A prospective observational study

* Study setting: The study will be carried out in the department of critical care medicine, Benha university hospitals.
* Study time: The study time is set to a period of one year from March 2025 to March 2026.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients (age ≥ 18 years) undergoing mechanical ventilation for ≥ 48 hours. * Patients admitted to ICU for * medical * trauma * surgical conditions. Exclusion Criteria: * Age below 18 years. * extracorporeal life support (ECLS). * Incomplete or inconsistent daily monitoring data. * Patients with confirmed or suspected respiratory viral infections (e.g., influenza, COVID-19). * undergoing palliative care or with a do-not-intubate (DNI) status. * Pregnant patients due to altered physiological responses. * Patients ventilated for less than 48 hours. * chronic ventilator dependency prior to ICU admission. * incomplete medical documentation impacting data collection or outcome analysis. * severe immunosuppression, such as recent bone marrow or organ transplant recipients, and those on high-dose corticosteroids.

Primary outcome measure(s)

  • Ventilator-Free Days at Day 28 (VFD-28) — at Day 28
    Ventilator-Free Days at Day 28 (VFD-28): The number of days a patient is alive and free from mechanical ventilation within the first 28 days after initiation of mechanical ventilation. Patients who die before day 28 will be assigned a value of zero VFDs.
  • * Prolonged Mechanical Ventilation — for 7 days
    \* Prolonged Mechanical Ventilation (≥7 Days): The proportion of patients requiring mechanical ventilation for 7 days or more.

Trial sites (1)

FacilityCityRegionStatus
Benha university Banhā Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07212881 on ClinicalTrials.gov ↗ ← All trials in Egypt